<DOC>
	<DOC>NCT00411073</DOC>
	<brief_summary>This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.</brief_summary>
	<brief_title>Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30 Signed and dated written informed consent prior to admission to the study Subject is able to understand and comply with protocol requirements, instructions and protocolstated restrictions cardiac abnormalities history of asthma or severe allergic reactions history of alcohol or drug abuse use of prescription or nonprescription drugs or vitamins or herbal supplements history of cholecystectomy or biliary tract disease pregnant or nursing women history of allergy to the study drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>darapladib</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>QT study</keyword>
</DOC>